Daniela C. Vittori

Daniela C. Vittori

Auto-generated profile, based on publicly available information

Daniela C. Vittori

Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto del Departamento de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN), Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2012 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
DVDaiana M. Vota
Daiana M. Vota
RMRomina E. Maltaneri
Romina E. Maltaneri
SWShirley D. Wenker
Shirley D. Wenker
ANAlcira B. Nesse
Alcira B. Nesse
DVDaniela C. Vittori
Daniela C. Vittori

19 July 2021 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
DVDaniela C. Vittori
Daniela C. Vittori
MCMaría E. Chamorro
María E. Chamorro
YHYender V. Hernández
Yender V. Hernández
RMRomina E. Maltaneri
Romina E. Maltaneri
ANAlcira B. Nesse
Alcira B. Nesse
Erythropoietin (Epo), the main erythropoiesis‐stimulating factor widely prescribed to overcome anemia, is also known nowadays for its cytoprotective action on non‐hematopoietic tissues. In this context, Epo showed not only its ability to cross the blood‐brain barrier, but also its expression in the brain of mammals. In clinical trials, recombinant Epo treatment has been shown to stimulate neurogenesis; improve cognition; and activate antiapoptotic, antioxidant, and anti‐inflammatory signaling pathways. These mechanisms, proposed to characterize a neuroprotective property, opened new perspectives on the Epo pharmacological potencies. However, many questions arise about a possible physiological role of Epo in the central nervous system (CNS) and the factors or environmental conditions that induce its expression. Although Epo may be considered a strong candidate to be used against neuronal damage, long‐term treatments, particularly when high Epo doses are needed, may induce thromboembolic complications associated with increases in hematocrit and blood viscosity. To avoid these adverse effects, different Epo analogs without erythropoietic activity but maintaining neuroprotection ability are currently being investigated. Carbamylated erythropoietin, as well as alternative molecules like Epo fusion proteins and partial peptides of Epo, seems to match this profile. This review will focus on the discussion of experimental evidence reported in recent years linking erythropoietin and CNS function through investigations aimed at finding benefits in the treatment of neurodegenerative diseases. In addition, it will review the proposed mechanisms for novel derivatives which may clarify and, eventually, improve the neuroprotective action of Epo. image


15 December 2011 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
DVDaiana M. Vota
Daiana M. Vota
RCRenée L. Crisp
Renée L. Crisp
ANAlcira B. Nesse
Alcira B. Nesse
DVDaniela C. Vittori
Daniela C. Vittori

14 July 2011 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
RMRosella Mechelli
Rosella Mechelli
JAJ Anderson
J Anderson
DVD Vittori
D Vittori
GCG Coarelli
G Coarelli
VAV Annibali
V Annibali
GRGiovanni Ristori
Giovanni Ristori
Background: Compared with quantitative observations, the search for qualitative changes that may characterize the immune response to Epstein–Barr virus (EBV) in multiple sclerosis (MS) has been less intense. Objective: To examine the B-cell epitopes of antibodies against the Epstein–Barr nuclear antigen-1 (EBNA-1) and their relevance for MS, through a study in disease-discordant identical twins. Methods: We evaluated the antibodies to all unique, maximally overlapping octapeptides of EBNA-1 in 12 pairs of monozygotic (MZ) twins (9 MS-discordant, 3 healthy), 3 non-twin patients and 2 healthy subjects. All except one of the patients were untreated. The EBV serology of these individuals had been assessed in advance using commercially available and in-house enzyme-linked immunosorbent assay (ELISA) kits, including assays for antibodies against select peptides of EBNA-1: EBNA-72 (GAGGGAGAGG) and EBNA-206 (EADYFEYHQEGGPDGE). Results: The glycine–alanine rich domain of EBNA-1 was immunodominant in all subjects. Compared with healthy individuals, and similarly to what has been described in infectious mononucleosis (IM) patients, affected co-twins and non-twin patients had a significantly increased response to another EBNA-1 epitope (aa. 401–411). Conclusion: In a study that controls for confounders, our data focus an EBNA-1 specificity that may be associated with MS pathogenesis.

8 February 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
GRGiovanni Ristori
Giovanni Ristori
SBSonia Brescianini
Sonia Brescianini
APA. Pino
A. Pino
AVAndrea Visconti
Andrea Visconti
DVD. Vittori
D. Vittori
MSMarco Salvetti
Marco Salvetti
Background: Metals are suspected of being involved in the pathogenesis of various neurologic diseases. We previously found a complex imbalance in serum chemical elements and oxidative status in patients with clinically definite multiple sclerosis (CDMS). Objective: To understand whether this imbalance affects people with clinically isolated syndrome (CIS) and, if so, whether it predicts conversion to CDMS. Methods: We studied 22 chemical elements and the oxidative status in 49 patients with CIS, 49 patients with CDMS, and 49 healthy donors (HD). Univariate and multivariate approaches were used to identify profiles for each group. A logistic regression analysis was used to identify the predictive potential of baseline data (elements, oxidative status, and MRI findings) for conversion to CDMS over 36 months. Results: Several elements and oxidative status values differed significantly among the 3 groups. Discriminant analysis revealed a major contribution of Ca, Fe, Sn, Zn, serum antioxidant capacity, and serum oxidative status, which resulted in distinct profiles (the prediction of group membership was 96% [cross-validated 92%] for HD, 92% [cross-validated 92%] for CDMS, and 90% [cross-validated 86%] for CIS). A weighted combination of element concentrations and oxidative status values, adjusting for all other predictors, would predict a reduction in the risk of conversion to CDMS within 3 years (odds ratio 0.37; 95% confidence interval 0.18–0.76; p = 0.007), thereby proving more effective than MRI at baseline. Conclusions: The peculiar imbalance in serum elements and oxidative status that characterizes patients with CIS and may predict conversion to CDMS warrants studies on larger sample sizes.